B
BSE
44,404.74
Last Updated on 02 Aug 2025 at 13:18
Open at
44,450.58
52W High
46,018.05
52W Low
37,028.95
Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.
High
45,574.07
Low
43,861.96
Open at
44,450.58
Prev Close
45,372.03
Volumes
0
Avg Price
0.00
Lower Circuit
0.00
Upper Circuit
0.00
Quantity
0
Time
13:18:31
3 M High
46,018.05
3 M Low
40,362.80
1 Yr High
46,018.05
1 Yr Low
37,028.95
3 Yr High
46,018.05
3 Yr Low
21,394.21
5 Yr High
46,018.05
5 Yr Low
18,284.23
Positive Stocks
24
Negative Stocks
85
Neutral Stocks
0
KMCH Issues Corrigendum for AGM Notice, Corrects Secretarial Auditor Term Duration
Kovai Medical Center and Hospital Limited has issued a corrigendum to correct an error in its Annual General Meeting notice for FY 2024-25. The term of appointment for the Secretarial Auditor has been amended to read from 2025-26 to 2029-30, instead of the previously stated 2025-26 to 2030-2031. The company has updated its Annual Report incorporating this change and made it available on the company website. The correction was communicated to BSE Limited and shareholders via email.
Torrent Pharmaceuticals' Vizag Facility Clears USFDA Inspection Without Observations
Torrent Pharmaceuticals announced that the USFDA has completed its inspection of the company's Vizag facility with no observations. This indicates that the facility met all regulatory standards during the inspection process.
Vijaya Diagnostic Centre Reports Strong Q1 FY26 Results with 20.4% Revenue Growth
Vijaya Diagnostic Centre Limited delivered consolidated revenue of Rs. 188 crores for the quarter ended June 30, 2025, representing a 20.4% year-on-year growth. The company achieved an EBITDA margin of 39.1% and PAT margin of 20.4%. Revenue growth was driven by 17% test volume growth and 14% patient footfall increase, along with changes in test mix. The Hyderabad market returned to double-digit growth this quarter. The company commissioned five new hubs and one spoke during the quarter across Pune, Bangalore, and West Bengal. Radiology contributed 39% of revenue mix while pathology accounted for 61%. The Nizamabad hub center achieved breakeven within two quarters of operations. One Bangalore hub center is on track to reach breakeven earlier than the estimated 12-month timeline. The company maintains its plan to open 10 hubs in the current financial year. Cash position stood at Rs. 270 crores as of June 30, 2025, with net cash of Rs. 220 crores after capital creditors. Wellness segment contributed 14.2% to revenue compared to 13.5% in the previous year. The company guided for CAPEX of Rs. 150-155 crores for new centers in FY26, with replacement CAPEX at 2-3% of topline.
Advanced Enzyme Technologies Reports 17% Growth in Q1 Net Profit
Advanced Enzyme Technologies reported consolidated net profit of Rs 399.3 million for Q1, representing a year-over-year increase from Rs 341.5 million in the same quarter last year.
Sanofi India Reports 9% Decline in Net Sales Despite 6% Growth in Operating Profit
Sanofi India Limited announced its financial results for the quarter ended June 30, 2025, showing a 9% decline in net sales on a comparable basis of continuing business. However, the company achieved a 6% increase in operating profit for the year-to-date period, driven by cost optimization and enhanced operational efficiencies. In the domestic market, the company saw success with the launch of Soliqua, a premium diabetes treatment, while Toujeo maintained strong performance with high single-digit growth. Strategic partnerships in Cardiovascular and Central Nervous System segments met expectations for market reach expansion. Export sales were negatively impacted by non-recurring CHC product sales from 2024 and the planned discontinuation of the Zentiva portfolio. The company continues its transformation through targeted market initiatives, operational excellence, and innovation advancement in India.
View More
Period | Simple | Signal |
---|---|---|
5-SMA | 20.92 | Bullish |
10-SMA | 21.62 | Bearish |
20-SMA | 23.95 | Bearish |
50-SMA | 24.94 | Bearish |
100-SMA | 21.62 | Bearish |
200-SMA | 16.57 | Bullish |
Indicator | Value | Action |
---|---|---|
RSI(14) | 31.66 | Neutral |
ATR(14) | 0.65 | Less Volatile |
STOCH(9,6) | 14.50 | Oversold |
STOCH RSI(14) | 22.26 | Neutral |
MACD(12,26) | -0.39 | Bearish |
ADX(14) | 38.91 | Strong Trend |
Summary of Technical Indicators for BSE HC
BSE HC Gainers | LTP | Change% | Weightage | Market Cap (Cr.) | PE Ratio | 52W High | 52W Low |
---|---|---|---|---|---|---|---|
H Hester Biosciences | 2,183.15 | 11.96% | 0.057% | ₹ 1,658.20 | 59.63 | 3,250.00 | 1,246.75 |
I Indegene | 576.30 | 5.98% | 0.447% | ₹ 13,035.70 | 31.34 | 736.60 | 485.15 |
P Procter & Gamble Health | 6,199.70 | 5.09% | 0.336% | ₹ 9,786.20 | 37.66 | 6,107.55 | 4,912.30 |
O Orchid Pharma | 777.10 | 5.00% | 0.129% | ₹ 3,755.20 | 37.66 | 1,998.00 | 603.80 |
A Advanced Enzyme Tech | 360.25 | 2.71% | 0.135% | ₹ 3,923.70 | 29.98 | 571.15 | 257.85 |
M Global Health | 1,340.00 | 2.22% | 1.209% | ₹ 35,217.20 | 67.92 | 1,392.00 | 936.05 |
A Artemis Medicare Services | 243.70 | 2.03% | 0.114% | ₹ 3,321.20 | 40.14 | 348.30 | 208.75 |
M Metropolis Healthcare | 2,035.00 | 1.88% | 0.355% | ₹ 10,336.00 | 73.98 | 2,306.85 | 1,383.70 |
T Tarsons Products | 370.90 | 1.56% | 0.067% | ₹ 1,945.80 | 65.21 | 527.15 | 282.00 |
G GPT Healthcare | 179.20 | 1.56% | 0.050% | ₹ 1,448.60 | 25.82 | 206.50 | 126.15 |
N Narayana Hrudayalaya | 1,939.10 | 1.20% | 1.365% | ₹ 39,758.40 | 49.87 | 2,371.60 | 1,171.35 |
L Dr. Lal Path Labs | 3,185.60 | 1.15% | 0.906% | ₹ 26,396.80 | 51.42 | 3,645.00 | 2,295.10 |
K Krishna Institute of Medical Sciences | 757.95 | 1.01% | 1.032% | ₹ 30,058.40 | 79.74 | 798.00 | 404.12 |
S Sanofi Consumer Healthcare | 4,950.00 | 0.89% | 0.388% | ₹ 11,303.40 | 60.28 | 5,954.00 | 4,360.30 |
L Lincoln Pharmaceuticals | 538.50 | 0.74% | 0.037% | ₹ 1,068.50 | 13.00 | 975.00 | 500.00 |
V Vijaya Diagnostic Centre | 1,083.40 | 0.70% | 0.379% | ₹ 11,039.40 | 73.24 | 1,276.75 | 763.10 |
P Poly Medicure | 1,949.80 | 0.58% | 0.674% | ₹ 19,634.90 | 58.03 | 3,350.00 | 1,788.05 |
K KMC Speciality Hospitals | 64.35 | 0.42% | 0.036% | ₹ 1,045.10 | 48.92 | 95.00 | 57.00 |
S Suraksha Diagnostic | 301.95 | 0.27% | 0.054% | ₹ 1,567.40 | 49.29 | 449.00 | 233.15 |
M Max Healthcare Institute | 1,246.95 | 0.25% | 4.158% | ₹ 1,21,129.50 | 106.86 | 1,314.30 | 837.00 |
K Kovai Medical Center Hospital | 6,260.65 | 0.21% | 0.235% | ₹ 6,834.70 | 32.61 | 6,515.00 | 4,279.45 |
F Fortis Healthcare | 859.25 | 0.21% | 2.222% | ₹ 64,733.90 | 76.76 | 859.85 | 480.45 |
F FDC | 479.00 | 0.17% | 0.268% | ₹ 7,804.30 | 29.18 | 659.00 | 358.95 |
E Eris Lifesciences | 1,802.65 | 0.03% | 0.841% | ₹ 24,500.50 | 70.09 | 1,909.55 | 1,035.00 |
Sectors | Companies | Weightage | Market Cap (Cr.) |
---|---|---|---|
Healthcare | 85 | 81.15% | 23,64,092.40 |
Healthcare Services | 24 | 18.85% | 5,49,058.80 |
Close Price
Volume
BSE HC share price in last 10 trading sessions
Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025 | -7.67% | -8.59% | 8.40% | 1.91% | 0.93% | 3.88% | 2.51% | -2.44% | NA | NA | NA | NA | -2.23% |
2024 | 7.18% | 3.74% | -0.08% | 1.01% | -1.46% | 6.37% | 9.19% | 6.56% | 2.45% | -0.72% | -0.57% | 3.69% | 43.51% |
2023 | -2.35% | -3.96% | 1.31% | 5.26% | 2.81% | 9.01% | 7.45% | 0.57% | 2.16% | -4.30% | 11.38% | 3.87% | 36.97% |
2022 | -8.02% | -3.10% | 4.06% | 0.15% | -7.70% | -3.83% | 6.00% | 0.49% | 1.42% | 2.50% | 0.09% | -3.81% | -12.10% |
2021 | -4.85% | 1.10% | 2.27% | 10.33% | 4.27% | 4.30% | 2.22% | 1.58% | -1.80% | -4.06% | 1.87% | 2.76% | 20.87% |
2020 | 3.93% | -3.42% | -9.88% | 26.21% | 2.05% | 3.94% | 12.43% | 0.56% | 7.68% | -2.73% | 5.51% | 6.71% | 61.45% |
2019 | -0.30% | -0.87% | 4.70% | -0.28% | -7.39% | -3.12% | -1.43% | 1.35% | -2.97% | 5.89% | 2.83% | -1.28% | -3.55% |
2018 | -1.62% | -3.07% | -6.77% | 7.57% | -8.13% | 7.70% | 1.44% | 12.24% | -5.77% | -1.99% | -2.67% | -2.86% | -5.92% |
2017 | 0.47% | 3.97% | -0.47% | -1.91% | -9.69% | 4.62% | 0.03% | -7.37% | 2.57% | 5.89% | -2.04% | 5.78% | 0.49% |
2016 | -3.55% | -6.73% | -0.38% | 2.86% | -2.16% | 1.62% | 5.20% | -0.84% | 0.12% | 1.80% | -4.48% | -6.40% | -12.88% |
1 Week
1 Month
3 Month
6 Month
9 Month
1 Year
2 Years
3 Years
4 Years
5 Years
1 Week
1 Month
3 Month
6 Month
9 Month
Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.
Name | LTP | Change | Change % | 1M Returns | 3M Returns | 6M Returns | 1Y Returns | 3Y Returns | 5Y Returns |
---|---|---|---|---|---|---|---|---|---|
B BSE Healthcare | ₹ 44,404.74 | -967.29 | -2.13% | 0.39% | 5.74% | 6.12% | 9.28% | 93.52% | 141.49% |
F Finnifty | ₹ 26,492.50 | -157.45 | -0.59% | - | - | - | - | - | - |
N Nifty Bank | ₹ 55,617.60 | -344.35 | -0.62% | - | - | - | - | - | - |
N Nifty 50 | ₹ 24,565.35 | -203.00 | -0.82% | - | - | - | - | - | - |
N NIFTY 100 | ₹ 25,149.60 | -230.90 | -0.91% | - | - | - | - | - | - |
N Nifty Next 50 | ₹ 66,192.80 | -903.35 | -1.35% | - | - | - | - | - | - |
Name | LTP | Change% | High | Low |
---|---|---|---|---|
B BSE Healthcare | ₹ 44,404.74 | -2.13% | ₹ 45,574.07 | ₹ 43,861.96 |
H Hester Biosciences | ₹ 2,183.15 | 11.96% | ₹ 2,332.60 | ₹ 1,852.00 |
I Indegene | ₹ 576.30 | 5.98% | ₹ 584.80 | ₹ 557.15 |
P Procter & Gamble Health | ₹ 6,199.70 | 5.09% | ₹ 6,490.00 | ₹ 5,901.00 |
O Orchid Pharma | ₹ 777.10 | 5.00% | ₹ 777.10 | ₹ 777.10 |
A Advanced Enzyme Tech | ₹ 360.25 | 2.71% | ₹ 366.55 | ₹ 352.75 |
G Global Health | ₹ 1,340.00 | 2.22% | ₹ 1,358.70 | ₹ 1,300.05 |
A Artemis Medicare Services | ₹ 243.70 | 2.03% | ₹ 251.80 | ₹ 236.35 |
M Metropolis Healthcare | ₹ 2,035.00 | 1.88% | ₹ 2,044.00 | ₹ 1,995.35 |
T Tarsons Products | ₹ 370.90 | 1.56% | ₹ 381.00 | ₹ 365.05 |
G GPT Healthcare | ₹ 179.20 | 1.56% | ₹ 184.80 | ₹ 170.75 |
Pay Zero Brokerage on Delivery
Open FREE Demat Account
+91
Or Scan the QR Code to download the Dhan App
Explore | Sitemap
*All securities mentioned on this website are exemplary and not recommendatory.
*Current prices on the website are delayed by 15 mins, login to check live prices.
We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.
Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.
That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.
©2021-2025 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services.
In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.
Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.
DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances
Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit
Attention investors:
Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.
Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.
Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/
Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX
Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets